Neurocrine Biosciences Inc
NBIXNeurocrine Biosciences Inc (NBIX) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological and endocrine disorders. Founded in 1992, the company specializes in innovative therapies for conditions such as Parkinson's disease, Tourette syndrome, and endometriosis, leveraging expertise in neuroscience and endocrine biology.
Company News
Fundstrat Capital completed its May 2026 quarterly rebalance of the Fundstrat Granny Shots US Small- & Mid-Cap ETF (GRNJ), adding 10 stocks including First Solar, Zoom, Credo Technology, and Neurocrine Biosciences, while removing 8 positions. CIO Tom Lee positions the portfolio for a 'challenging but ultimately constructive' environment, with the...
Nxera Pharma reported strong Q1 2026 results with revenue of JPY 11.3 billion, a significant increase from the prior year, driven by seven R&D milestone events. The company signed a licensing agreement with Santhera for vamorolone in APAC markets, achieved positive Phase 3 results for daridorexant in South Korea, and received milestone payments f...
Neurocrine Biosciences has initiated a Phase 2 clinical trial of NBI-1117570, a dual muscarinic M1/M4 receptor agonist discovered by Nxera Pharma, for treating schizophrenia. Nxera will receive $22.5 million in milestone payments from Neurocrine as a result of this achievement.
Soleno Therapeutics agreed to be acquired by peer Neurocrine Biosciences for $2.9 billion, or $53 per share in an all-cash deal, representing a 34% premium. The acquisition is driven by Soleno's FDA-approved drug Vykat XR for treating hyperphagia in Prader-Willi Syndrome patients. Soleno's stock surged 32% on the announcement, and the deal is exp...
Neurocrine Biosciences announced its acquisition of Soleno Therapeutics for $2.9 billion ($53 per share in cash) to expand its rare disease portfolio with Vykat XR, an FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The deal is expected to close within 90 days. Vykat XR generated $190 million in revenue in 2025, demonstrating str...
